Conformational fingerprinting of ACE can identify tissue-specific origins of the enzyme in blood and detect functionally altered ACE in diseases like uremia.
Enables blood detection of non-pulmonary ACE sources; leaves open diagnostic utility in sarcoidosis and uremia.
The binding pattern of the set of 16 monoclonal antibodies to the different epitopes on the surface of two domains of angiotensin-converting enzyme, i.e., conformational fingerprinting, allows to reveal in blood the presence of an enzyme that is not produced by lung endothelial cells, but rather by other cells, e.g., Gaucher’s cells and sarcoid granuloma cells. The existence of angiotensin-converting enzyme with changed conformation in the blood of patients with uremia has been shown; this enzyme was characterized by enhanced activity towards angiotensin I and decreased ability to be inhibited by specific inhibitors. The prospects of discovering conformationally changed enzyme in blood of patients with atrial fibrillation have also been discussed.
No takes yet. Share an insight, caveat, or question.
Кост et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: